BioStock:Cereno Scientific obtains rights to inlicense preclinical candidate
Cereno Scientific announced last week that it has signed an option agreement with the University of Michigan granting Cereno Scientific the rights to evaluate a new drug candidate in a preclinical development program during a time period of up to 27 months. The agreement signals a push by the company to expand its development portfolio.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se